These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 17218487)

  • 1. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
    Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ
    J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice.
    Rhee CK; Lee SH; Yoon HK; Kim SC; Lee SY; Kwon SS; Kim YK; Kim KH; Kim TJ; Kim JW
    Respiration; 2011; 82(3):273-87. PubMed ID: 21659722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.
    Daniels CE; Wilkes MC; Edens M; Kottom TJ; Murphy SJ; Limper AH; Leof EB
    J Clin Invest; 2004 Nov; 114(9):1308-16. PubMed ID: 15520863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia.
    Vuorinen K; Gao F; Oury TD; Kinnula VL; Myllärniemi M
    Exp Lung Res; 2007 Sep; 33(7):357-73. PubMed ID: 17849262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate.
    Bhattacharyya S; Ishida W; Wu M; Wilkes M; Mori Y; Hinchcliff M; Leof E; Varga J
    Oncogene; 2009 Mar; 28(10):1285-97. PubMed ID: 19151753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of prosurvival signaling in fibroblasts by a protein kinase inhibitor protects against fibrotic tissue injury.
    Vittal R; Horowitz JC; Moore BB; Zhang H; Martinez FJ; Toews GB; Standiford TJ; Thannickal VJ
    Am J Pathol; 2005 Feb; 166(2):367-75. PubMed ID: 15681821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
    Aono Y; Nishioka Y; Inayama M; Ugai M; Kishi J; Uehara H; Izumi K; Sone S
    Am J Respir Crit Care Med; 2005 Jun; 171(11):1279-85. PubMed ID: 15735062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells.
    Kinoshita K; Nakagawa K; Hamada J; Hida Y; Tada M; Kondo S; Moriuchi T
    Int J Oncol; 2010 Oct; 37(4):869-77. PubMed ID: 20811709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate inhibits proliferation and exerts an antifibrotic effect in human breast stroma fibroblasts.
    Gioni V; Karampinas T; Voutsinas G; Roussidis AE; Papadopoulos S; Karamanos NK; Kletsas D
    Mol Cancer Res; 2008 May; 6(5):706-14. PubMed ID: 18505916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
    Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
    Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib attenuates severe mouse dystrophy and inhibits proliferation and fibrosis-marker expression in muscle mesenchymal progenitors.
    Ito T; Ogawa R; Uezumi A; Ohtani T; Watanabe Y; Tsujikawa K; Miyagoe-Suzuki Y; Takeda S; Yamamoto H; Fukada S
    Neuromuscul Disord; 2013 Apr; 23(4):349-56. PubMed ID: 23313020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
    Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
    Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib mesylate inhibited rat adjuvant arthritis and PDGF-dependent growth of synovial fibroblast via interference with the Akt signaling pathway.
    Terabe F; Kitano M; Kawai M; Kuwahara Y; Hirano T; Arimitsu J; Hagihara K; Shima Y; Narazaki M; Tanaka T; Kawase I; Sano H; Ogata A
    Mod Rheumatol; 2009; 19(5):522-9. PubMed ID: 19568828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate attenuates myocardial remodeling through inhibition of platelet-derived growth factor and transforming growth factor activation in a rat model of hypertension.
    Jang SW; Ihm SH; Choo EH; Kim OR; Chang K; Park CS; Kim HY; Seung KB
    Hypertension; 2014 Jun; 63(6):1228-34. PubMed ID: 24591339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
    Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy.
    van Steensel L; Paridaens D; Schrijver B; Dingjan GM; van Daele PL; van Hagen PM; van den Bosch WA; Drexhage HA; Hooijkaas H; Dik WA
    Invest Ophthalmol Vis Sci; 2009 Jul; 50(7):3091-8. PubMed ID: 19234339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo.
    Wang S; Wilkes MC; Leof EB; Hirschberg R
    FASEB J; 2005 Jan; 19(1):1-11. PubMed ID: 15629889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
    Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
    Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.